About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

102.45 +0.19 (+0.19%)
Streaming Delayed Price Updated: 10:51 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Top 3 Health Care Stocks That Are Preparing To Pump This Month ↗
 
Via Benzinga
News headline image
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst ↗
Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a major strategic move. 
Via Benzinga
News headline image
Discover the top movers in Thursday's pre-market session. ↗
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Exact Sciences's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Groupon Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 16% year on year to $811.1 million. The company’s... 
Via StockStory
News headline image
Exact Sciences (EXAS) Q2 Revenue Up 16% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
How Exact Sciences Is Spending $775 Million To Dominate The Cancer-Screening Market ↗
The company is expanding its oncology efforts with a deal for a blood-based colorectal cancer screening test. 
Via Investor's Business Daily
Topics Earnings
News headline image
Exact Sciences Announces Second Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences (EXAS) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
From Exact Sciences Corp.
Via Business Wire
News headline image
3 Cash-Producing Stocks We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
News headline image
Exact Sciences Schedules Second Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
News headline image
1 Healthcare Stock for Long-Term Investors and 2 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
News headline image
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
From Exact Sciences Corp.
Via Business Wire
News headline image
Forecasting The Future: 9 Analyst Projections For Exact Sciences ↗
 
Via Benzinga
News headline image
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out ↗
BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences. 
Via Benzinga
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Topics Economy
News headline image
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Mid-Cap Stocks in the Doghouse
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences to Participate in June Investor Conference
From Exact Sciences Corp.
Via Business Wire
News headline image
3 Low-Volatility Stocks Walking a Fine Line
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.